Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

NCT07756346 is registered in ClinicalTrials.gov with University of Massachusetts, Worcester as lead sponsor.

NCT NCT07756346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07756346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa
Lead sponsor
University of Massachusetts, Worcester
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
April 30, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)